Consensus Cronos Group Inc. Nasdaq

Equities

CRON

CA22717L1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.59 ^USD	+3.60%		+9.28%	+23.92%

Apr. 02	Cannabis Stocks: Wedbush Notes Florida Supreme Court Approved Proposed Amendment For Adult Use Cannabis to be Placed on the 2024 General Election Ballot	MT
Mar. 25	Cronos Group Brief: Launching 'Lord Jones' Chocolate Fusions	MT

Evolution of the average Target Price on Cronos Group Inc.

Price target over the last 5 years

History of analyst recommendation changes

9bb7e48416f468da0c134.NHWOX-ssG7I6vRXbt1s31gelIYVOOUF_SV_2_N22LxA.BircarEfUJ9X-GHq4QhiuEvMU84Id3IdDi-mlZX5Z2BiJqMnjhhwg3bqcg~f6fb09cf3463055978695895126040e9

Analyst Recommendations on Cronos Group Inc.

Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	Mar. 22	MT
Bernstein Starts Cronos Group at Market Perform with CA$4.10 Price Target	22-11-02	MT
Barclays Adjusts Cronos Group's Price Target to $3.50 from $5, Maintains Equalweight Rating	22-09-30	MT
Cronos Group Price Target Raised to $7 at Raymond James	22-07-29	MT
CIBC Upgrades Cronos Group to Outperform From Neutral	22-05-12	MT
Raymond James Adjusts Cronos Group Price Target to $6 From $5, Maintains Outperform Rating	22-05-09	MT
Barclays Upgrades Cronos Group to Equalweight From Underweight	22-03-22	MT
Piper Sandler Lowers Cronos Target to US$3 on Cash Flow Outlook, Maintains Neutral Rating	22-03-07	MT
Piper Sandler Adjusts Cronos Group Price Target to $3 From $4, Maintains Neutral Rating	22-03-07	MT
CORRECTION : --Canaccord Genuity Adjusts Cronos Group's Price Target to CA$4.25 from CA$7, Maintains Sell Rating	22-02-22	MT
Canaccord Genuity Adjusts Cronos Group's Price Target to $4.25 from $7, Maintains Sell Rating	22-02-22	MT
Stifel Adjusts Cronos Group's Price Target to $4 From $6.50, Reiterates Hold Rating	22-02-22	MT
Piper Sandler Adjusts Cronos Group's Price Target to $4 From $7, Maintains Neutral Rating	22-02-22	MT
Cronos Group Neutral Rating Reiterated by Piper Sandler Following Q3 Results, Q2 Restatement	22-02-18	MT
Jefferies Upgrades Cronos Group to Hold From Underperform	22-01-27	MT
Cannabis Stocks Brief: Barclays Initiates Underwhelming Ratings on Canada Cannabis Cos Due To Difficulties In Having US Multi-State Operations, Citing Canopy Growth Recent Moves, BNN TV notes	21-11-23	MT
Cronos Brief: Initiated With Underweight Rating and Target of US$5 at Barclays, notes BNN TV	21-11-23	MT
Barclays Starts Cronos Group at Underweight With $5.50 Price Target	21-11-18	MT
Cannabis Brief: BNN Also Notes Sector Expected To Operate At An Annual Run Rate of Near $8-9 Billion Over Next Few Years, "Despite Profitability Challenges"	21-09-23	MT
Cannabis Brief: BNN Notes the Sector Operates At An Annual Run Rate of Near $4 Billion, Showing Market Continues To Grow	21-09-23	MT
CRONOS : BofA Securities Starts Cronos Group at Underperform with $7.50 Price Target	21-04-28	MT
CRONOS : CIBC Downgrades Cronos Group to Neutral From Outperform, Adjusts Price Target to $12.50 From $8	21-02-22	MT